The purpose of national follow-up of a new pharmaceutical is to evaluate whether the pharmaceutical has been used according to the New Therapies Council's recommendation and whether introduction has been achieved according to the ethical principles.
Planning the follow-up
Planning the follow-up of a new pharmaceutical that will be covered by national joint introduction is often done in collaboration with the Dental and Medical Benefits Agency (TLV), the National Board of Health and Welfare (Socialstyrelsen) and the National Quality Registries (Nationella Kvalitetsregister). The parties agree on parameters to follow up, survey questions, identify data sources and division of responsibilities.
The follow-up is planned alongside the development of the recommendation. The follow-up instructions to the regions state what level of follow-up is required, and which parameters that can be followed up if resources allow.
Scope of the follow-up
The purpose of a national follow-up of a new pharmaceutical is to clarify whether the pharmaceutical has been used in accordance with the national recommendations, for the correct patient group (indications, contraindications) and in the correct way (dose, dose intensity). Sometimes, but less often, safety and efficacy are also followed up.
Due to limited access to data, not all medicines covered by national joint introduction can be followed up in this way. However, the regions are provided with sales statistics for all medicines that are handled by the New Therapies Council.
Length of follow-up
In general, the follow-up should last for two to three years. The follow-up results are reported back to the New Therapies Council and conveyed to the regions. Some reports are published on this website.